December, 2023

No. 108 (12)

2022 CiteScore: 13.3 2022 Impact Factor: 10.1



Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients

In clonal hematopoiesis (CH), somatically mutated hematopoietic stem or progenitor cells form a clonal subpopulation of blood cells. Stelmach and colleagues analyzed a large cohort of stem cell grafts collected for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients to identify associations between CH and blood cell regeneration. Their results demonstrated that CH with DNMT3A and PPM1D mutations correlates with reduced stem cell yields and delayed platelet count recovery following ASCT, indicating an impaired regenerative potential of hematopoietic stem cell grafts harboring CH.

Patrick Stelmach et al.


Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma

Carfilzomib, a second-generation proteasome inhibitor (PI), is associated with higher rates of cardiovascular adverse events (AE) in patients with multiple myeloma (MM) compared to other PI. Khan and colleagues conducted a retrospective analysis to assess incidence of cardiovascular AE and outcomes of MM patients treated with carfilzomib using a step-up titration dosing (TD) schedule compared to standard dosing (SD). They found no differences in incidence of cardiovascular AE but a longer overall survival in the TD group.

Abdullah M. Khan et al.


Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment

Studies on the circulating metabolome in sickle cell disease (SCD) have identified potential new avenues for metabolic interventions; however, they have a limited sample size and there is a paucity of extensively curated clinical data. D’Alessandro and colleagues present a metabolomics study on 596 SCD patients, for whom extensive clinical, biological and therapeutics information was available. Their study provides an extensive overview of the plasma metabolome in SCD and its clinical correlation, suggesting new avenues for metabolic interventions in this patient population.

Angelo D’Alessandro et al.


CD47 expression in acute myeloid leukemia varies according to genotype

CD47 is a “don’t eat me” signal to phagocytes, representing a key mechanism of immune evasion in cancer. Anti-CD47 blocking monoclonal antibodies are effective against acute myeloid leukemia (AML) in preclinical models, and several clinical trials are ongoing. Marra and colleagues performed a detailed immunohistochemical characterization of CD47 protein expression on leukemic cells across distinct genomic subtypes of AML, supported by bulk transcriptome analysis of leukemic cells from AML patients included in the Beat-AML dataset. They provide a potentially useful guide to immunotherapeutic approaches targeting CD47 in AML.

Andrea Marra et al.